Chief Executive Stephane Bancel says Moderna will work with the Trump administration. Moderna stock rose in midday trades.

The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.

Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Attorney General Peter Neronha has joined 13 other state prosecutors in a new lawsuit targeting Elon Musk, DOGE and President ...

Zoetis said on Friday its bird flu vaccine has received the U.S. Department of Agriculture's conditional license for use in poultry.

Moderna shares fell after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2.91 per share, ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...

Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled manufacturing contract.

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...